In recent years, artificial intelligence has shown itself as a transformative force across various sectors, and it is now making significant inroads into traditional practices, such as Traditional Chinese Medicine (TCM). The emergence of companies like Wenzhi TCM exemplifies this burgeoning intersection of technology and heritage, as it aims to harness AI's potential to enhance the accessibility and effectiveness of TCM servicesFounded in 2018, Wenzhi TCM has positioned itself as a significant player in the TCM industry, recently filing to go public and aiming to become the first AI-powered TCM company listed on the Hong Kong Stock ExchangeHowever, as it strives to innovate in an ancient field, the path is fraught with challenges that merit a closer examination.

Wenzhi TCM has established a business model that integrates modern technology with time-honored medical practicesLeveraging AI, the company offers virtual consultations through video calls, phone interactions, and even tongue diagnosticsThis approach promises to enhance the distribution of high-quality healthcare resources, potentially transforming the patient experience by making consultations more efficient and accessibleDespite these ambitions, the company faces significant hurdles, including a challenging financial outlook marked by persistent losses that total over 400 million yuan within its first three years of operation.

The company’s financial statements reveal that Wenzhi TCM’s primary revenues are derived from its core TCM medical services, which account for more than 80% of its revenue from 2022 to the first three quarters of 2024. The numbers show that while patient visits increased significantly—rising from just over 61,000 in 2022 to nearly 174,000 in 2023—the revenue per patient has also grown, indicating a rising demand for their servicesHowever, the company's gross profit margin in medical services remains relatively low compared to other segments of their business, contributing to an ongoing struggle to achieve profitability.

As detailed in their prospectus, the high costs associated with pharmaceutical materials and employee welfare significantly impact the bottom line

Advertisements

Employee benefits alone consumed over 32% of their revenue in 2023, and marketing expenses were another substantial drain, highlighting the financial pressures that come with competing in a crowded marketFundraising has been critical for Wenzhi TCM, which has raised approximately $21.7 million across five funding rounds since its inception, with its most recent round garnering $12 million in late 2024.

Industry analysts have expressed skepticism regarding Wenzhi TCM’s ability to maintain momentum amidst fierce competitionContinuous losses and tight cash flows mean that reliance on outside funding as a lifeline is unsustainable in the long termThe core question remains: How will Wenzhi TCM develop a competitive advantage that allows for sustainable profitability, especially while burning through capital? The answer may lie in the company's research and development strategy.

Wenzhi TCM has touted its proprietary “TCM Brain” platform, which utilizes AI-driven assistance to enhance diagnostic accuracy and personalize treatment plans, drawing from a vast repository of over a billion parameters and more than 10,000 formulasThe hope is that this technological foundation will fortify their market position; however, the current level of investment in R&D appears lackluster compared to their operational costsFor instance, in the first three quarters of 2024, R&D expenditures were only about 4.9% of revenue, raising concerns about whether they can innovate fast enough to stay ahead of competitors.

The rollout of Wenzhi TCM’s various services showcases a blend of online convenience and offline accessibilitySince receiving its internet medical license in 2021, the company has expanded its clientele significantly, engaging clients in 339 cities across ChinaTheir online capabilities represent a substantial share of their operations, with diagnostic services comprising nearly 94% of their total revenue during peak periodsIn practical terms, they offer a one-stop service for patients, inclusive of consultations, prescriptions, and even herbal medicine preparation through their specialized centers.

Despite these advancements, actual user experiences paint a varied picture

Advertisements

Reports of patient dissatisfaction, ranging from ineffective treatments to logistical issues with medication deliveries, underline the gap between Wenzhi TCM’s ambitious technological promises and the grounded realities faced by its consumersAn account from a patient suffering from kidney stones indicates frustration with ongoing treatment costs without visible improvements, suggesting that the perceived efficacy is not always aligned with the narratives promoted by the company.

While Wenzhi TCM's focus on patient retention appears strong—boasting a higher recidivism rate than the industry average—it remains to be seen what this means for long-term patient loyalty and brand integrityComplaints around service delivery, such as issues with herbal preparation and drug quality, cast a shadow over their operational competenceThe prospectus outlines efforts to address these challenges, indicating a dual approach designed to harmonize online platforms with traditional in-clinic services, hoping to create a seamless experience for the patientsHowever, the company’s physical expansion since its first clinic opened in 2019 has been sluggish, with only a handful of locations operating by early 2025.

Industry competition is formidable, with Wenzhi TCM capturing just 1.5% of the domestic market share, despite being the largest AI-enabled TCM provider in ChinaThe overall sector remains highly dispersed with over 12,600 TCM service providers engaging in various forms of AI integration but still operating within an early-development phaseThe discrepancy between Wenzhi TCM's ambitions and the realities of competing against both established players and emerging startups reveals an uphill battle in a fragmented market that is ripe for disruption but also rife with uncertainty.

Experts caution that the integration of AI into TCM practices must tackle inherent complexities within the diagnostic processes unique to Traditional Chinese Medicine

Advertisements

Advertisements

Advertisements